Phio Pharmaceuticals Corp.

Healthcare · Biotechnology · United States

Last price 0.8626 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.02M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name...